Corimmun, a Germany-based drug development company backed by High-Tech Gründerfonds,, has been sold to Janssen-Cilag, part of the Janssen Pharmaceutical Companies of US-based pharmaceutical group Johnson & Johnson. Corimmun received €680,000 ($855,000) of funding in 2008 from High-Tech Gründerfonds, Bayern Kapital and BioM in 2007. Corimmun’s main product is Cor-1, a peptide for the treatment…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
